Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Oct;14(10):825-9.
doi: 10.3779/j.issn.1009-3419.2011.10.10.

[The utilization and limitation of CD133 epitopes in lung cancer stem cells research]

[Article in Chinese]
Yin Chen  1 , Hong Zhong
Affiliations
Review

[The utilization and limitation of CD133 epitopes in lung cancer stem cells research]

[Article in Chinese]
Yin Chen et al. Zhongguo Fei Ai Za Zhi. 2011 Oct.

Abstract
in English, Chinese

Lung cancer is one of the most common tumor, which lacks of effective clinical treatment to lead to desirable prognosis. According to cancer stem cell hypothesis, lung cancer stem cells are considered to be responsible for carcinogenesis, development, metastasis, recurrence, invasion, resistance to chemotherapy and radiotherapy of lung cancer. In recent years, more and more institutes used glycosylated CD133 epitopes to define, isolate, purify lung cancer stem cells. However, along with deeply research, the application of CD133 epitopes in lung cancer stem cell research is questioned. The utilization and limitation of CD133 epitopes in lung cancer stem cells research for the past few years is summaried in this review.

肺癌是临床上最常见的恶性肿瘤之一，尚缺乏预后较为理想的治疗方案。肿瘤干细胞学说认为肺癌干细胞是肺癌发生、发展、转移、复发、耐受放化疗以及肺癌细胞具有侵袭性的主要原因。近年来越来越多的机构利用CD133糖基化表位来鉴定、分离、提纯肺癌干细胞。然而，随着研究的深入，CD133作为肺癌干细胞标记物逐渐受到质疑。本文对近年来利用CD133作为肺癌干细胞表面标记物的应用及其局限性做一综述。

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–236. doi: 10.3322/caac.v61:4. - DOI - PubMed
    1. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–111. doi: 10.1038/35102167. - DOI - PubMed
    1. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancel stem cells. J Mol Med. 2008;86(9):1025–1032. doi: 10.1007/s00109-008-0357-8. - DOI - PMC - PubMed
    1. Tirino V, Desiderio V, Paino F, et al. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 2011;25(6):2022–2030. doi: 10.1096/fj.10-179036. - DOI - PubMed
    1. Shi CJ, Gao J, Wang M, et al. CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity. World J Gastroenterol. 2011;17(24):2965–2971. doi: 10.3748/wjg.v17.i24.2965. - DOI - PMC - PubMed